These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5484240)

  • 1. [Study of the microbe factor in the process of plasma fractionation and several problems of pyrogenicity of blood preparations].
    Margolina AN; Kozlova MA; Sirotenko AV; Golosova TV; From AA
    Probl Gematol Pereliv Krovi; 1970 Jul; 15(7):9-13. PubMed ID: 5484240
    [No Abstract]   [Full Text] [Related]  

  • 2. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An industry perspective on plasma-derived products.
    von Hoegen I
    Dev Biol (Basel); 2004; 118():31-5. PubMed ID: 15645670
    [No Abstract]   [Full Text] [Related]  

  • 5. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of medicinal products derived from human blood or plasma in the European Community.
    Brunko P
    Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813
    [No Abstract]   [Full Text] [Related]  

  • 7. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Viral safety concept: application to blood and blood products].
    Trouvin JH
    Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Process validation.
    Beatrice MG
    Dev Biol Stand; 1998; 96():169-71; discussion 177-9. PubMed ID: 9890529
    [No Abstract]   [Full Text] [Related]  

  • 11. A proposal for the Polish norm of PKA and KK content in plasma-derived preparations.
    Aleksandrowicz J; Fiejka M
    Rocz Panstw Zakl Hig; 1992; 43(3-4):311-5. PubMed ID: 1308750
    [No Abstract]   [Full Text] [Related]  

  • 12. [THE PRINCIPLE OF OBTAINING PREPARATIONS FROM DONOR BLOOD PLASMA BY FRACTIONATION BY AN EXTRACHAMBER METHOD].
    ROZENBERG GIa; PODOLSKII MV
    Probl Gematol Pereliv Krovi; 1963 Apr; 8():3-9. PubMed ID: 14060633
    [No Abstract]   [Full Text] [Related]  

  • 13. The EEC and the regulation of blood derivatives.
    Horaud F
    Dev Biol Stand; 1993; 81():273-6. PubMed ID: 8174814
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationships among product characterization, process validation and preclinical/clinical studies for well-characterized products.
    Lubiniecki AS
    Dev Biol Stand; 1998; 96():173-5; discussion 177-9. PubMed ID: 9890530
    [No Abstract]   [Full Text] [Related]  

  • 15. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.
    Mazurier C
    Semin Thromb Hemost; 2006 Jul; 32(5):529-36. PubMed ID: 16862527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The temperature stability of bovine parvovirus].
    Bräuniger S; Fischer I; Peters J
    Zentralbl Hyg Umweltmed; 1994 Oct; 196(3):270-8. PubMed ID: 7848502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story.
    Flesland O; Seghatchian J; Solheim BG
    Transfus Apher Sci; 2003 Feb; 28(1):93-100. PubMed ID: 12620274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma-derived biological medicines used to promote haemostasis.
    Ofosu FA; Freedman J; Semple JW
    Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A universal virus inactivant for decontaminating blood and biopharmaceutical products.
    Brown F; Meyer RF; Law M; Kramer E; Newman JF
    Dev Biol Stand; 1999; 99():119-30. PubMed ID: 10404883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.